Drug intelligence / Profile preview

ZK2501

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Administration: Oral

Overview

ZK2501 is a preclinical-stage therapeutic candidate being developed by Lee's Pharmaceutical for the treatment of solid tumors. As of 2024, the asset is in the early stages of development, and specific details regarding its molecular target and modality have not been publicly disclosed by the sponsor. It is part of Lee's Pharmaceutical's internal oncology pipeline, which includes several early-stage assets aimed at addressing unmet needs in cancer therapy.

Beyond the preview

Go deeper on ZK2501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK2501.

Explore the full profile